-DOCSTART- -X- O
Highly -X- _ O
pathogenic -X- _ O
avian -X- _ O
influenza -X- _ O
( -X- _ O
HPAI -X- _ O
) -X- _ O
viruses -X- _ O
of -X- _ O
the -X- _ O
H5N1 -X- _ O
subtype -X- _ O
often -X- _ O
cause -X- _ O
severe -X- _ O
pneumonia -X- _ O
and -X- _ O
multiple -X- _ O
organ -X- _ O
failure -X- _ O
in -X- _ O
humans -X- _ O
, -X- _ O
with -X- _ O
reported -X- _ O
case -X- _ O
fatality -X- _ O
rates -X- _ O
of -X- _ O
more -X- _ O
than -X- _ O
60 -X- _ O
% -X- _ O
. -X- _ O
To -X- _ O
develop -X- _ O
a -X- _ O
clinical -X- _ O
antibody -X- _ O
therapy -X- _ O
, -X- _ O
we -X- _ O
generated -X- _ O
a -X- _ O
human-mouse -X- _ B-Intervention
chimeric -X- _ I-Intervention
monoclonal -X- _ I-Intervention
antibody -X- _ I-Intervention
( -X- _ I-Intervention
MAb -X- _ I-Intervention
) -X- _ I-Intervention
ch61 -X- _ I-Intervention
that -X- _ O
showed -X- _ O
strong -X- _ O
neutralizing -X- _ O
activity -X- _ O
against -X- _ O
H5N1 -X- _ O
HPAI -X- _ O
viruses -X- _ O
isolated -X- _ O
from -X- _ O
humans -X- _ O
and -X- _ O
evaluated -X- _ O
its -X- _ O
protective -X- _ O
potential -X- _ O
in -X- _ O
mouse -X- _ O
and -X- _ O
nonhuman -X- _ O
primate -X- _ O
models -X- _ O
of -X- _ O
H5N1 -X- _ O
HPAI -X- _ O
virus -X- _ O
infections. -X- _ O
Passive -X- _ O
immunization -X- _ O
with -X- _ O
MAb -X- _ B-Intervention
ch61 -X- _ I-Intervention
one -X- _ B-Outcome
day -X- _ I-Outcome
before -X- _ I-Outcome
or -X- _ I-Outcome
after -X- _ I-Outcome
challenge -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
lethal -X- _ I-Outcome
dose -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
virus -X- _ I-Outcome
completely -X- _ I-Outcome
protected -X- _ I-Outcome
mice -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
partial -X- _ I-Outcome
protection -X- _ I-Outcome
was -X- _ I-Outcome
achieved -X- _ I-Outcome
when -X- _ I-Outcome
mice -X- _ I-Outcome
were -X- _ I-Outcome
treated -X- _ I-Outcome
3 -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
the -X- _ I-Outcome
challenge. -X- _ I-Outcome
In -X- _ O
a -X- _ O
cynomolgus -X- _ O
macaque -X- _ O
model -X- _ O
, -X- _ O
reduced -X- _ B-Outcome
viral -X- _ I-Outcome
loads -X- _ I-Outcome
and -X- _ I-Outcome
partial -X- _ I-Outcome
protection -X- _ I-Outcome
against -X- _ I-Outcome
lethal -X- _ I-Outcome
infection -X- _ I-Outcome
were -X- _ I-Outcome
observed -X- _ I-Outcome
in -X- _ I-Outcome
macaques -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
MAb -X- _ I-Outcome
ch61 -X- _ I-Outcome
intravenously -X- _ I-Outcome
one -X- _ I-Outcome
and -X- _ I-Outcome
three -X- _ I-Outcome
days -X- _ I-Outcome
after -X- _ I-Outcome
challenge. -X- _ I-Outcome
Protective -X- _ O
effects -X- _ O
were -X- _ O
also -X- _ O
noted -X- _ O
in -X- _ O
macaques -X- _ O
under -X- _ O
immunosuppression. -X- _ O
Though -X- _ O
mutant -X- _ O
viruses -X- _ O
escaping -X- _ O
from -X- _ O
neutralization -X- _ O
by -X- _ O
MAb -X- _ O
ch61 -X- _ O
were -X- _ O
recovered -X- _ O
from -X- _ O
macaques -X- _ O
treated -X- _ O
with -X- _ O
this -X- _ O
MAb -X- _ O
alone -X- _ O
, -X- _ O
combined -X- _ B-Outcome
treatment -X- _ I-Outcome
with -X- _ I-Outcome
MAb -X- _ I-Outcome
ch61 -X- _ I-Outcome
and -X- _ I-Outcome
peramivir -X- _ I-Outcome
reduced -X- _ I-Outcome
the -X- _ I-Outcome
emergence -X- _ I-Outcome
of -X- _ I-Outcome
escape -X- _ I-Outcome
mutants. -X- _ I-Outcome
Our -X- _ O
results -X- _ O
indicate -X- _ O
that -X- _ O
antibody -X- _ O
therapy -X- _ O
might -X- _ O
be -X- _ O
beneficial -X- _ O
in -X- _ O
reducing -X- _ O
viral -X- _ O
loads -X- _ O
and -X- _ O
delaying -X- _ O
disease -X- _ O
progression -X- _ O
during -X- _ O
H5N1 -X- _ O
HPAI -X- _ O
virus -X- _ O
infection -X- _ O
in -X- _ O
clinical -X- _ O
cases -X- _ O
and -X- _ O
combined -X- _ O
treatment -X- _ O
with -X- _ O
other -X- _ O
antiviral -X- _ O
compounds -X- _ O
should -X- _ O
improve -X- _ O
the -X- _ O
protective -X- _ O
effects -X- _ O
of -X- _ O
antibody -X- _ O
therapy -X- _ O
against -X- _ O
H5N1 -X- _ O
HPAI -X- _ O
virus -X- _ O
infection -X- _ O
. -X- _ O

